About Advaxis (NASDAQ:ADXS)
Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers. The company is also developing Axalimogene filolisbac for the treatment of anal cancer; ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is designed to target the prostate specific antigen associated with prostate cancer; and ADXS-NEO, an individualized Lm technology antigen delivery product candidate that is designed to create individualized therapies by activating the patient's immune system to respond against multiple mutations or neoantigens. In addition, it is developing ADXS-HOT for generating potent anti-cancer immunity; and ADXS-HER2, an Lm technology antigen delivery product candidate that is designed to target HER2 expressing solid tumors, including human and canine osteosarcoma. The company has collaboration and licensing agreements with Bristol-Myers Squibb Company; Amgen Inc.; Sellas Life Science Group; Merck & Co., Inc.; MedImmune/AstraZeneca PLC; Especificos Stendhal SA de CV; Aratana Therapeutics Inc.; and Global BioPharma Inc. Advaxis, Inc. was founded in 2002 and is based in Princeton, New Jersey.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADXS
CUSIPN/A
Phone609-452-9813
Debt
Debt-to-Equity RatioN/A
Current Ratio2.96%
Quick Ratio2.96%
Price-To-Earnings
Trailing P/E Ratio-0.71
Forward P/E Ratio-0.95
P/E GrowthN/A
Sales & Book Value
Annual Sales$12.03 million
Price / Sales7.13
Cash FlowN/A
Price / CashN/A
Book Value$1.32 per share
Price / Book1.24
Profitability
EPS (Most Recent Fiscal Year)($2.31)
Net Income$-93,430,000.00
Net Margins-940.64%
Return on Equity-149.14%
Return on Assets-92.30%
Miscellaneous
Employees108
Outstanding Shares52,310,000
Advaxis (NASDAQ:ADXS) Frequently Asked Questions
What is Advaxis' stock symbol?
Advaxis trades on the NASDAQ under the ticker symbol "ADXS."
How were Advaxis' earnings last quarter?
Advaxis (NASDAQ:ADXS) released its quarterly earnings data on Monday, March, 12th. The biotechnology company reported ($0.49) EPS for the quarter, topping analysts' consensus estimates of ($0.55) by $0.06. The biotechnology company had revenue of $2.06 million for the quarter, compared to the consensus estimate of $3.03 million. Advaxis had a negative return on equity of 149.14% and a negative net margin of 940.64%. View Advaxis' Earnings History.
When is Advaxis' next earnings date?
What price target have analysts set for ADXS?
2 Wall Street analysts have issued 1-year price objectives for Advaxis' stock. Their forecasts range from $5.00 to $6.00. On average, they anticipate Advaxis' share price to reach $5.50 in the next year. View Analyst Ratings for Advaxis.
What are Wall Street analysts saying about Advaxis stock?
Here are some recent quotes from research analysts about Advaxis stock:
- 1. HC Wainwright analysts commented, "Olga Smolentseva, Ph.D. – (646-975-6966) / [email protected] ADXS-NEO Can Incite Immune Responses With Non-Immunogenic" Antigens; Reiterate Buy ADXS-NEO demonstrates potential in two preclinical studies. On April 16, Advaxis presented results from two preclinical studies of ADXS-NEO at the 2018 American Association for Cancer Research (AACR) Annual Meeting. Recall, ADXS-NEO is a personalized therapy targeting tumor neoantigens developed from Advaxis’ Lm-LLO listeria delivery platform. ADXS-NEO was licensed to Amgen (AMGN; not rated) in 2016 for $40M upfront and up to $475M in development, regulatory and sales milestone payments and up to mid-double-digit royalties on worldwide sales. In the first of the two studies, the company demonstrated that ADXS-NEO is able to target frameshift mutations and drive a neoantigen-specific antitumor immune response in MC38 and CT26 mouse tumor models." (4/17/2018)
- 2. Cantor Fitzgerald analysts commented, "Multiple inflection points expected in 2018, including an update on the AIM2CERV Phase III study and potential preliminary data from Part B of the Phase I/II study of ADXS-PSA in combination with Keytruda." (9/25/2017)
Who are some of Advaxis' key competitors?
Some companies that are related to Advaxis include Immune Design (IMDZ), Proteostasis Therapeutics (PTI), Intec Pharma (NTEC), XBiotech (XBIT), NewLink Genetics (NLNK), Newron Pharmaceuticals (NWPHF), Tetraphase Pharmaceuticals (TTPH), Acer Therapeutics (ACER), Zynerba Pharmaceuticals (ZYNE), Aldeyra Therapeutics (ALDX), BioXcel Therapeutics (BTAI), Galectin Therapeutics (GALT), Sierra Oncology (SRRA), Affimed (AFMD), Aeglea Bio Therapeutics (AGLE), BioDelivery Sciences International (BDSI), Adamis Pharmaceuticals (ADMP) and Checkpoint Therapeutics (CKPT).
Who are Advaxis' key executives?
Advaxis' management team includes the folowing people:
- Ms. Sara M. Bonstein, Exec. VP, Principal Accounting Officer, CFO & Corp. Sec. (Age 37)
- Dr. Robert G. Petit, Exec. VP & Chief Scientific Officer (Age 58)
- Mr. Anthony A. Lombardo, Interim Chief Exec. Officer (Age 69)
- Mr. Christopher Duke, Sr. VP & COO
- Mr. Mayo Pujols, Sr. VP of Technical Operations
Has Advaxis been receiving favorable news coverage?
Press coverage about ADXS stock has trended somewhat positive recently, according to Accern Sentiment. The research group identifies positive and negative media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Advaxis earned a media sentiment score of 0.13 on Accern's scale. They also gave media stories about the biotechnology company an impact score of 46.88 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Advaxis?
Shares of ADXS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Advaxis' stock price today?
One share of ADXS stock can currently be purchased for approximately $1.64.
How big of a company is Advaxis?
Advaxis has a market capitalization of $88.41 million and generates $12.03 million in revenue each year. The biotechnology company earns $-93,430,000.00 in net income (profit) each year or ($2.31) on an earnings per share basis. Advaxis employs 108 workers across the globe.
How can I contact Advaxis?
Advaxis' mailing address is 305 COLLEGE ROAD EAST, PRINCETON NJ, 08540. The biotechnology company can be reached via phone at 609-452-9813 or via email at [email protected]
MarketBeat Community Rating for Advaxis (ADXS)
MarketBeat's community ratings are surveys of what our community members think about Advaxis and other stocks. Vote "Outperform" if you believe ADXS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADXS will underperform the S&P 500 over the long term. You may vote once every thirty days.
Advaxis (NASDAQ:ADXS) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Advaxis (NASDAQ ADXS) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 7.21%
Institutional Ownership Percentage: 29.13%
Advaxis (NASDAQ ADXS) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/2/2018 | Robert Petit | Insider | Sell | 2,193 | $1.62 | $3,552.66 | |  |
| 2/2/2018 | Anthony A Lombardo | CEO | Sell | 32 | $2.93 | $93.76 | 92,903 | |
| 1/3/2018 | Sara Bonstein | CFO | Sell | 5,224 | $3.18 | $16,612.32 | 229,237 | |
| 11/6/2017 | Robert Petit | Insider | Sell | 3,723 | $3.30 | $12,285.90 | 220,917 | |
| 11/6/2017 | Sara Bonstein | CFO | Sell | 3,862 | $3.30 | $12,744.60 | 227,908 | |
| 11/2/2017 | Anthony A Lombardo | CEO | Sell | 24 | $3.19 | $76.56 | 92,935 | |
| 11/2/2017 | Robert Petit | Insider | Sell | 12,625 | $3.19 | $40,273.75 | 237,265 | |
| 11/2/2017 | Sara Bonstein | CFO | Sell | 12,734 | $3.19 | $40,621.46 | 244,504 | |
| 10/11/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Sell | 600,000 | $4.30 | $2,580,000.00 | | |
| 9/26/2017 | Adage Capital Partners Gp, L.L | Major Shareholder | Sell | 1,239,323 | $4.42 | $5,477,807.66 | | |
| 3/31/2017 | Robert Petit | Insider | Sell | 2,454 | $8.24 | $20,220.96 | 122,051 | |
| 12/30/2016 | Sara Bonstein | CFO | Sell | 5,520 | $7.37 | $40,682.40 | 131,963 | |
| 12/20/2016 | Thomas J Mckearn | Director | Sell | 12,316 | $8.08 | $99,513.28 | 69,804 | |
| 11/2/2016 | Daniel O'connor | CEO | Sell | 8,240 | $8.32 | $68,556.80 | 303,127 | |
| 11/2/2016 | Robert Petit | Insider | Sell | 2,797 | $8.32 | $23,271.04 | 123,659 | |
| 10/25/2016 | Gregory T Mayes | Insider | Sell | 19,162 | $8.23 | $157,703.26 | 103,087 | |
| 8/9/2016 | David Sidransky | Director | Sell | 22,808 | $15.01 | $342,348.08 | 91,759 | |
| 8/8/2016 | Richard J Berman | Director | Sell | 18,000 | $15.21 | $273,780.00 | 66,430 | |
| 5/13/2016 | Thomas J Mckearn | Director | Sell | 4,100 | $7.45 | $30,545.00 | 82,120 | |
| 5/2/2016 | Daniel O'connor | CEO | Sell | 8,237 | $7.51 | $61,859.87 | 316,661 | |
| 5/2/2016 | Robert Petit | Insider | Sell | 2,785 | $7.51 | $20,915.35 | 128,025 | |
| 3/31/2016 | Robert Petit | Insider | Sell | 3,325 | $9.13 | $30,357.25 | 131,164 | |
| 3/16/2016 | Thomas J Mckearn | Director | Sell | 14,000 | $8.25 | $115,500.00 | 86,220 | |
| 2/24/2016 | Sara Bonstein | CFO | Sell | 15,037 | $5.58 | $83,906.46 | 79,980 | |
| 1/29/2016 | Daniel O'connor | CEO | Sell | 8,818 | $6.88 | $60,667.84 | 313,394 | |
| 1/29/2016 | Robert Petit | insider | Sell | 3,099 | $6.88 | $21,321.12 | 130,557 | |
| 10/26/2015 | Gregory T Mayes | COO | Sell | 19,231 | $11.63 | $223,656.53 | 119,821 | |
| 10/20/2015 | David J Mauro | Insider | Sell | 24,586 | $10.08 | $247,826.88 | 165,932 | |
| 8/24/2015 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 300,000 | $14.15 | $4,245,000.00 | | |
| 4/30/2015 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 500,000 | $19.00 | $9,500,000.00 | | |
| 2/18/2015 | Adage Capital Partners Gp Llc | Major Shareholder | Buy | 684,762 | $7.50 | $5,135,715.00 | | |
| 5/9/2014 | Richard J Berman | Director | Sell | 14,530 | $2.63 | $38,213.90 | | |
| 3/31/2014 | Daniel O'connor | CEO | Buy | 3,333 | $3.00 | $9,999.00 | | |
| 10/24/2013 | Daniel O'connor | CEO | Buy | 13,500 | $4.00 | $54,000.00 | | |
| 10/24/2013 | Mark J Rosenblum | CFO | Buy | 12,000 | $4.00 | $48,000.00 | | |
| 10/24/2013 | Robert Petit | Insider | Buy | 12,800 | $4.00 | $51,200.00 | | |
| 10/24/2013 | Roni Appel | Director | Buy | 12,500 | $4.00 | $50,000.00 | | |
(Data available from 1/1/2013 forward)
Advaxis (NASDAQ ADXS) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | $2.43 Million in Sales Expected for Advaxis (ADXS) This Quarter
www.americanbankingnews.com - April 20 at 4:28 AM |
 | Advaxis (ADXS) Says Preclinical Data Highlighting ADXS-Hot as Immunotherapy Presented in Poster Discussion at ...
www.streetinsider.com - April 18 at 9:36 AM |
| Advaxis (ADXS) Expected to Post Earnings of -$0.41 Per Share
www.americanbankingnews.com - April 18 at 9:35 AM |
 | Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting
finance.yahoo.com - April 17 at 9:22 AM |
| Advaxis' (ADXS) "Buy" Rating Reaffirmed at HC Wainwright
www.americanbankingnews.com - April 17 at 7:39 AM |
| Advaxis (ADXS) Rating Lowered to Sell at BidaskClub
www.americanbankingnews.com - April 15 at 12:36 AM |
| Advaxis (ADXS) Downgraded by ValuEngine
www.americanbankingnews.com - April 8 at 9:37 AM |
| What Is The Future Prospect For Healthcare And Advaxis Inc (NASDAQ:ADXS)?
finance.yahoo.com - April 4 at 4:51 PM |
| Analysts Expect Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $2.43 Million
www.americanbankingnews.com - April 3 at 4:11 AM |
 | Data Highlighting Advaxis' ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology ...
www.businesswire.com - April 2 at 10:01 AM |
| Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting
finance.yahoo.com - April 2 at 10:01 AM |
| -$0.41 Earnings Per Share Expected for Advaxis, Inc. (ADXS) This Quarter
www.americanbankingnews.com - April 1 at 7:23 AM |
| Advaxis Inc (NASDAQ:ADXS): Does The -36.80% Earnings Drop Reflect A Longer Term Trend?
finance.yahoo.com - March 27 at 9:12 AM |
| Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018
finance.yahoo.com - March 26 at 10:09 AM |
| Advaxis (ADXS) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM |
| Advaxis (ADXS) PT Lowered to $5.00
www.americanbankingnews.com - March 18 at 12:26 PM |
| Edited Transcript of ADXS earnings conference call or presentation 12-Mar-18 8:30pm GMT
finance.yahoo.com - March 18 at 9:40 AM |
| Zacks: Brokerages Anticipate Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $2.43 Million
www.americanbankingnews.com - March 17 at 8:38 AM |
| FY2018 EPS Estimates for Advaxis, Inc. Lifted by Cantor Fitzgerald (ADXS)
www.americanbankingnews.com - March 16 at 10:48 AM |
| Q2 2018 Earnings Estimate for Advaxis, Inc. (ADXS) Issued By Jefferies Group
www.americanbankingnews.com - March 15 at 7:54 AM |
| Zacks: Brokerages Anticipate Advaxis, Inc. (ADXS) Will Post Earnings of -$0.59 Per Share
www.americanbankingnews.com - March 15 at 5:18 AM |
| Advaxis (ADXS) Given a $6.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - March 14 at 10:50 PM |
 | Advaxis shares drop as cancer-drug study on hold after death - MarketWatch
www.marketwatch.com - March 14 at 12:18 PM |
| Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac ... - Business Wire (press release)
www.businesswire.com - March 14 at 12:18 PM |
 | Mid-Day Market Update: Crude Oil Down 1.5%; Proteostasis Therapeutics Shares Spike Higher
www.benzinga.com - March 13 at 4:58 PM |
 | Advaxis' (ADXS) CEO Tony Lombardo on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - March 13 at 10:54 AM |
| Advaxis to Present at Upcoming March Conferences
finance.yahoo.com - March 13 at 10:54 AM |
| Advaxis shares drop as cancer-drug study on hold after death
finance.yahoo.com - March 13 at 10:54 AM |
| Advaxis (ADXS) Issues Quarterly Earnings Results
www.americanbankingnews.com - March 13 at 10:20 AM |
 | Technical Perspectives on Biotech Stocks -- 22nd Century, Abeona Therapeutics, Advaxis, and Adverum Biotechnologies
www.bizjournals.com - March 12 at 4:43 PM |
| Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)
finance.yahoo.com - March 12 at 4:43 PM |
| Should You Have Advaxis Inc’s (NASDAQ:ADXS) In Your Portfolio?
finance.yahoo.com - March 12 at 4:43 PM |
| Advaxis reports 1Q loss
finance.yahoo.com - March 12 at 4:43 PM |
| Advaxis, Inc. (ADXS) Short Interest Update
www.americanbankingnews.com - March 12 at 1:24 AM |
| How Do Analysts See Advaxis Inc (NASDAQ:ADXS) Performing Over The Next Few Years?
finance.yahoo.com - March 9 at 4:54 PM |
| Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018
finance.yahoo.com - March 9 at 10:59 AM |
| Advaxis Inc (NASDAQ:ADXS): Is Breakeven Near?
finance.yahoo.com - March 8 at 10:32 AM |
| Advaxis (ADXS) Set to Announce Earnings on Thursday
www.americanbankingnews.com - March 1 at 1:30 AM |
| Brokerages Expect Advaxis, Inc. (ADXS) Will Announce Quarterly Sales of $3.03 Million
www.americanbankingnews.com - February 28 at 1:48 PM |
| The No BS Plan: Week 2 Report - The Advaxis Apocalypse Is Nigh?
seekingalpha.com - February 25 at 9:48 AM |
| Advaxis (ADXS) Prices 10M Offering of Common Stock at $2/Share
www.streetinsider.com - February 22 at 4:47 PM |
| Advaxis Prices $20.0 Million Public Offering of Common Stock
finance.yahoo.com - February 22 at 4:47 PM |
| Advaxis looks to raise $20 million via share offering
finance.yahoo.com - February 22 at 4:47 PM |
 | BRIEF-Advaxis Expects To Report $59.4 Million Of Cash, Cash Equivalents And Investments As Of Jan 31
www.reuters.com - February 22 at 9:12 AM |
| Advaxis (ADXS) Plans Offering of Common Stock
www.streetinsider.com - February 22 at 9:12 AM |
| Advaxis Announces Proposed Public Offering of Common Stock
finance.yahoo.com - February 21 at 4:45 PM |
| Advaxis (ADXS) Submits Conditional MAA for Axalimogene Filolisbac for Second-Line Treatment of Metastatic Cervical Cancer in EU
www.streetinsider.com - February 15 at 4:46 PM |
| 3 Things In Biotech You Should Learn Today: February 13, 2018
seekingalpha.com - February 15 at 4:46 PM |
| Advaxis (ADXS) Submits Conditional MAA for Axalimogene Filolisbac for Second-Line Treatment of Metastatic Cervical ... - StreetInsider.com
www.streetinsider.com - February 14 at 3:26 PM |
| Advaxis Takes Its First Step Towards Regulatory Approval - Seeking Alpha
seekingalpha.com - February 14 at 3:26 PM |
Advaxis (NASDAQ:ADXS) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Advaxis (NASDAQ:ADXS) Income Statement, Balance Sheet and Cash Flow Statement
Advaxis (NASDAQ ADXS) Stock Chart for Saturday, April, 21, 2018
Loading chart…
